ClinicalTrials.gg
TerminatedNCT06118099Updated Feb 4, 2026

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of Amlitelimab and Placebo in Hidradenitis, sponsored by Sanofi. Terminated at 42 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision; the decision is not related to any safety concern

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hidradenitis with a site in United States — 6 open to participants now, 10 under way, 5 of them phase 3. Hidradenitis · United States.

Enrollment
15th of 24
90 · median 153
Started
2023
with 1 other
Phase 2
9 of 25
3 open now
Registered
11th of 25
by date
Lead sponsor
2 of 25
Sanofi

Among the 25 studies in Hidradenitis with a site in United States, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 in phase 2, and was the 11th registered.

Hidradenitis

34 studies on the registry are indexed under Hidradenitis; 9 are open to participants now.

Browse Hidradenitis studies →

Open to participants now

6 of the 25 studies in Hidradenitis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Hidradenitis studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hidradenitis with a site in United States, or all of them as a file.
02

Study summary

This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS).

The purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), safety, and drug concentration. An optional long-term extension (LTE) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment.

Study details include:

  • The study duration will be up to 116 weeks, including a 4-week Screening period, a 16-week double-blind treatment period (DBT), an optional 80-week LTE period and a 16-week post-treatment follow-up period.
  • All participants who complete the 16-week DBT period will be offered entry into an optional LTE.
  • Participants who do not wish to enter the optional LTE period or who stop treatment prior to Week 16 (Visit 6) or stop investigational medicinal product (IMP) administration prior to completing the LTE period will proceed into the 16-week post-treatment follow-up period.
  • The number of planned in clinic visits will be up to six during the DBT period with an additional nine during the LTE period, plus one post-treatment follow-up end-of-study visit. Up to 11 optional in clinic visits are allowed for participants who do not wish to self-administer IMP between scheduled in clinic visits during the LTE period.
Read the detailed description

The study duration per participant will be up to 116 weeks.

03

Conditions studied

  • Hidradenitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 (or country's age of majority if >18) years to 70 years of age inclusive, at the time of signing the .
  • Participants with a history of signs and symptoms consistent with HS for at least 1 year prior to baseline.
  • Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), 1 of which must be Hurley Stage II or Hurley Stage III.
  • Participant must have had an inadequate response to at least a 12-week trial of an oral antibiotic for treatment of HS

Exclusion criteria

Exclusion Criteria:

  • Participants with a diagnosis of inflammatory conditions other than HS (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, multiple sclerosis, Behcet's disease, sarcoidosis, etc)
  • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Amlitelimab

    Subcutaneous injection (SC) as per protocol.

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Subcutaneous injection as per protocol.

    Drug: Placebo

Interventions

  • Injection solution SC injection

    Also known as: SAR445229

  • DrugPlacebo

    Injection solution SC injection

06

What researchers measure

Primary outcomes

  1. The clinical response as measured by the percentage of participants achieving HiSCR50 at Week 16

    Hidradenitis suppurativa clinical response (HiSCR)50 is defined as ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

Secondary outcomes

  1. Time to onset of achieving HiSCR50

    HiSCR50 is defined as ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.

    Time frame: From baseline to Week 16

  2. Absolute change from baseline in AN count at Week 16

    AN count is the total abscess and inflammatory nodule count.

    Time frame: Baseline to Week 16

  3. Percentage change in AN count at Week 16

    AN count is the total abscess and inflammatory nodule count.

    Time frame: Baseline to Week 16

  4. Percentage of participants achieving HiSCR75 at Week 16

    HiSCR75 is defined as ≥75% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  5. Percentage of participants achieving HiSCR90 at Week 16

    HiSCR90 is defined as ≥90% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  6. Percentage of participants who experience improvement by at least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) stage at Week 16

    The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.

    Time frame: Week 16

  7. Change in absolute score from Baseline in IHS4 at Week 16

    The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.

    Time frame: Baseline to Week 16

  8. Percentage of participants who experience a flare at Week 16

    A flare is defined as at least a 25% increase in AN count (with a minimum increase of 2 AN) relative to baseline. AN count is the total abscess and inflammatory nodule count.

    Time frame: Week 16

  9. Percentage of participants achieving IHS4-55 at Week 16

    IHS4-55 is defined as achievement of a 55% reduction in IHS4 score from baseline. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.

    Time frame: Week 16

  10. Percentage of participants achieving at least 30% reduction and at least 1 unit reduction from Baseline in weekly average of daily HS-Skin Pain NRS at Week 16 among participants with baseline NRS ≥3

    Hidradenitis Suppurativa-Skin pain-numeric rating scale (HS-Skin pain NRS) is scored on a 0 to 10 scale with 0 indicating "no skin pain" and 10 indicating "worst skin pain possible".

    Time frame: Week 16

  11. Percentage of participants with improvement (reduction) in Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 from Baseline at Week 16 among participants with baseline PP-NRS ≥4

    PP-NRS is a validated single item 0 (no itch) to10 (worst itch imaginable) numeric rating scale assessing peak pruritus (itch).

    Time frame: Week 16

  12. Percentage of participants who experience 5-point reduction in DLQI at Week 16 among participants with baseline DLQI ≥4

    Dermatology life quality index (DLQI) is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL). Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Week 16

  13. Change from Baseline in the total Hidradenitis Suppurativa Quality of Life (HiSQOL) score at Week 16

    HiSQOL is an instrument designed to measure the HS-specific health-related QoL of adults with HS.

    Time frame: Baseline to Week 16

  14. Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interest (AESIs), and serious adverse events (SAEs) including local injection site reactions in the Safety Population

    Time frame: Baseline up to Week 116

  15. Incidence of potentially clinically significant abnormalities in laboratory tests, vital signs, and electrocardiograms in the Safety Population

    Time frame: Baseline up to Week 116

  16. Serum amlitelimab concentrations measured at prespecified time points in the PK population

    Time frame: Day 1 up to Week 116

  17. Incidence of antidrug antibodies (ADA) of amlitelimab at prespecified timepoints in the ADA population

    Time frame: Day 1 up to Week 116

07

Study locations

42 sites
  • Medical Dermatology Specialists Site Number : 8400002
    Phoenix, Arizona 85006-2754, United States
  • Center for Dermatology Clinical Research Site Number : 8400010
    Fremont, California 94538-1614, United States
  • Corazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011
    Margate, Florida 33063, United States
  • Florida International Research Center Site Number : 8400016
    Miami, Florida 33173, United States
  • University of South Florida Site Number : 8400012
    Tampa, Florida 33612, United States
  • Beth Israel Deaconess Medical Center Site Number : 8400006
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine Site Number : 8400007
    St Louis, Missouri 63110, United States
  • Centricity Research Site Number : 8400009
    Dublin, Ohio 43016, United States
  • Clinical Partners, LLC Site Number : 8400003
    Johnston, Rhode Island 02919, United States
  • Vast Skin Specialists Site Number : 8400015
    Addison, Texas 75001, United States
  • Center for Clinical Studies, LTD. LLP Site Number : 8400001
    Houston, Texas 77004, United States
  • Stryde Research Epiphany Dermatology Site Number : 8400014
    Southlake, Texas 76092, United States
  • Investigational Site Number : 0360003
    Phillip, Australian Capital Territory 2606, Australia
  • Investigational Site Number : 0360001
    Darlinghurst, New South Wales 2010, Australia
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3004, Australia
  • Investigational Site Number : 1240007
    Barrie, Ontario L4M 7G1, Canada
  • Investigational Site Number : 1240002
    Hamilton, Ontario L8L 3C3, Canada
  • Investigational Site Number : 1240001
    Québec, G1W 4R4, Canada
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
  • Investigational Site Number : 2500005
    La Rochelle, 17019, France
  • Investigational Site Number : 2500003
    Lyon, 69003, France
  • Investigational Site Number : 2500001
    Reims, 51100, France
  • Investigational Site Number : 2500004
    Rouen, 76031, France
  • Investigational Site Number : 2500002
    Saint-Mandé, 94163, France
  • Investigational Site Number : 2760002
    Bochum, 44791, Germany
  • Investigational Site Number : 2760001
    Münster, 48149, Germany
  • Investigational Site Number : 3480004
    Budapest, 1083, Hungary
  • Investigational Site Number : 3480001
    Debrecen, 4032, Hungary
  • Investigational Site Number : 3480002
    Szeged, 6720, Hungary
  • Investigational Site Number : 3800001
    Catania, 95123, Italy
  • Investigational Site Number : 3800002
    Cona (Ferrara), 44124, Italy
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Investigational Site Number : 6160004
    Warsaw, 02-962, Poland
  • Investigational Site Number : 6160003
    Wroclaw, 50-566, Poland
  • Investigational Site Number : 6200002
    Lisbon, 1649-035, Portugal
  • Investigational Site Number : 6200001
    Lisbon, 1998-018, Portugal
  • Investigational Site Number : 7240001
    Barcelona, Barcelona [Barcelona] 08041, Spain
  • Investigational Site Number : 7240003
    Badalona, Catalunya [Cataluña] 08916, Spain
  • Investigational Site Number : 7240006
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
  • Investigational Site Number : 7240002
    Madrid, Madrid, Comunidad de 28046, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Nov 1, 2023
Primary completionActual
Feb 6, 2025
CompletionActual
Oct 10, 2025
Results delay requested
Jan 29, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118099
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Nov 1, 2023
Primary completion
Feb 6, 2025
Completion
Oct 10, 2025
Last update
Feb 4, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion